Foundation Medicine (FMI) Prelim. Q4, FY15 Revenue Exceeds Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Foundation Medicine Reports Preliminary 2015 Results and Provides 2016 Business Outlook, including Commercial Launch of its ctDNA Assay
January 11, 2016 6:30 AM ESTAchieves Revenue of Approximately $93.2 Million, a 53% Year Over Year Increase
Reports Approximately 33,000 Clinical Tests in 2015, a 36% Year Over Year Increase
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine (NASDAQ: FMI) today announced preliminary unaudited total revenue of approximately $26.1 million in the fourth quarter of 2015 and $93.2 million for the full year ended December 31, 2015, a 39% and 53%... More
